Early reports have shown that COVID-19 is most likely causing a hypercoagulable state, however the prevalence of acute VTE and exactly how to treat it is an evolving area. Limited data suggest pulmonary microvascular thrombosis may play a role in progressive respiratory failure.

However, most evidence is limited to small retrospective trials.

As we wait for more evidence, clinical decisions have to made at the bedside and decisions about pharmacological prophylaxis are starting to emerge.

In this episode I sit down with a special guest that is new to REBEL Cast to talk about the dilemmas involving COVID-19 and thrombosis.

It is reasonable to consider DVT prophylaxis for patients that providers feel are at higher risk for developing the severe form of COVID. And this is in complete agreement with JACC guidelines.

Read More